[go: up one dir, main page]

WO2008112166A3 - Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications - Google Patents

Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications Download PDF

Info

Publication number
WO2008112166A3
WO2008112166A3 PCT/US2008/003094 US2008003094W WO2008112166A3 WO 2008112166 A3 WO2008112166 A3 WO 2008112166A3 US 2008003094 W US2008003094 W US 2008003094W WO 2008112166 A3 WO2008112166 A3 WO 2008112166A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic
lipoate
metformin
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/003094
Other languages
French (fr)
Other versions
WO2008112166A2 (en
Inventor
Banavara L Mylari
Rao Mary E Vaman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indigene Pharmaceuticals Inc
Original Assignee
Indigene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indigene Pharmaceuticals Inc filed Critical Indigene Pharmaceuticals Inc
Priority to EP08726603A priority Critical patent/EP2134169A2/en
Publication of WO2008112166A2 publication Critical patent/WO2008112166A2/en
Publication of WO2008112166A3 publication Critical patent/WO2008112166A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are pharmaceutical compositions, methods, and kits comprising metformin R-(+) lipoate and an antihyperlipidemic agent or a pharmaceutically acceptable salt, hydrate, solvate and prodrug derivative thereof for the treatment of Type 2 diabetic hyperglycemia and diabetic complications.
PCT/US2008/003094 2007-03-09 2008-03-07 Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications Ceased WO2008112166A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08726603A EP2134169A2 (en) 2007-03-09 2008-03-07 Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90599007P 2007-03-09 2007-03-09
US60/905,990 2007-03-09

Publications (2)

Publication Number Publication Date
WO2008112166A2 WO2008112166A2 (en) 2008-09-18
WO2008112166A3 true WO2008112166A3 (en) 2008-10-30

Family

ID=39760278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003094 Ceased WO2008112166A2 (en) 2007-03-09 2008-03-07 Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications

Country Status (5)

Country Link
EP (1) EP2134169A2 (en)
AR (1) AR065670A1 (en)
CL (1) CL2008000684A1 (en)
TW (1) TW200901959A (en)
WO (1) WO2008112166A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085223A1 (en) * 2007-12-20 2009-07-09 Indigene Pharmaceuticals, Inc. Combination of metformin r-(+)-lipoate and antihyperglycemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2012073256A1 (en) * 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
WO2015001568A2 (en) * 2013-07-01 2015-01-08 Laurus Labs Private Limited Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
BR112021003265A2 (en) * 2018-08-24 2021-05-18 Esperion Therapeutics, Inc. Methods to Reduce Diabetes Risk in Patients Being Treated for High Cholesterol-Related Diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078269A1 (en) * 2001-03-22 2003-04-24 Chronorx, Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US20050182029A1 (en) * 2002-02-14 2005-08-18 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20060122181A1 (en) * 2003-04-09 2006-06-08 Japan Tobacco Inc. Heteroaromatic pentacyclic compound and medicinal use thereof
US20060280794A1 (en) * 2003-06-06 2006-12-14 Naoru Hamaguchi Solid pharmaceutical preparation

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2513251A (en) 1947-06-21 1950-06-27 Allied Chem & Dye Corp Preparation of pyridine carboxylic acids
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3308020A (en) 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US3716583A (en) 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (en) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarboxylic acid derivatives and processes for making the same
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4205064A (en) 1973-06-11 1980-05-27 Merck & Co., Inc. Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides]
JPS5612114B2 (en) 1974-06-07 1981-03-18
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
ES488665A0 (en) 1980-02-15 1980-12-16 Especialidades Farmaco Terape PROCEDURE FOR OBTAINING A NEW ANTI-AGES-CLEROTIC COMPOUND
MX7065E (en) 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
US4342771A (en) 1981-01-02 1982-08-03 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4367234A (en) 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4617312A (en) 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
AR240698A1 (en) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
US4703052A (en) 1985-05-21 1987-10-27 Pfizer Inc. Hypoglycemic thiazolidinediones
US4895723A (en) 1986-09-08 1990-01-23 Amer And Company Cholestyramine compositions and method for preparation thereof
JP2569746B2 (en) 1987-08-20 1997-01-08 日産化学工業株式会社 Quinoline mevalonolactones
US5268181A (en) 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
EP0583346A1 (en) 1991-04-12 1994-02-23 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
JP3727334B2 (en) 1992-04-22 2005-12-14 リガンド・ファーマシューティカルズ・インコーポレイテッド Compound having selectivity for retinoid X receptor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1997028137A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
ES2217392T3 (en) 1996-02-02 2004-11-01 MERCK & CO., INC. ANTIDIABETIC AGENTS.
ES2202582T3 (en) 1996-02-02 2004-04-01 MERCK & CO., INC. ANTIDIABETIC AGENTS.
ATE293963T1 (en) 1996-02-02 2005-05-15 Merck & Co Inc METHOD FOR TREATING DIABETES AND RELATED MEDICAL CONDITIONS.
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US6203785B1 (en) 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US6469035B1 (en) 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
TW438784B (en) 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6190649B1 (en) 1999-04-23 2001-02-20 Geltex Pharmaceuticals, Inc. Polyether-based bile acid sequestrants
FR2796551B1 (en) 1999-07-23 2003-07-25 Lipha NOVEL METFORMIN SALTS, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CO5271716A1 (en) 1999-11-30 2003-04-30 Pfizer Prod Inc CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED
HN2000000203A (en) 1999-11-30 2001-06-13 Pfizer Prod Inc PROCEDURE FOR OBTAINING 1,2,3,4-TETRAHYDROQUINOLINS 4-CARBOXYAMIN-2-SUBSTITUTED.
US6558659B2 (en) 2000-04-10 2003-05-06 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
CN1210260C (en) 2000-10-31 2005-07-13 西巴特殊化学品控股有限公司 Crystalline forms of fluvastatin sodium
AU2002219175A1 (en) 2000-12-21 2002-07-01 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
SI20848A (en) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Pharmaceutical formulation containing atorvastatin calcium
HU225777B1 (en) 2001-04-30 2007-08-28 Pfizer Prod Inc Compounds useful as intermediates for 4-aminoquinoline derivatwes and process for producing them
US7026295B2 (en) 2002-12-04 2006-04-11 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078269A1 (en) * 2001-03-22 2003-04-24 Chronorx, Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US20050182029A1 (en) * 2002-02-14 2005-08-18 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US20060122181A1 (en) * 2003-04-09 2006-06-08 Japan Tobacco Inc. Heteroaromatic pentacyclic compound and medicinal use thereof
US20060280794A1 (en) * 2003-06-06 2006-12-14 Naoru Hamaguchi Solid pharmaceutical preparation
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer

Also Published As

Publication number Publication date
EP2134169A2 (en) 2009-12-23
AR065670A1 (en) 2009-06-24
CL2008000684A1 (en) 2008-08-01
WO2008112166A2 (en) 2008-09-18
TW200901959A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2008115516A3 (en) 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
IL180916A0 (en) Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2008039489A3 (en) 5-substituted quinazolinone derivatives as antitumor agents
WO2008010921A3 (en) Modulators of pharmacokinetic properties of therapeutics
WO2008096001A8 (en) Hcv inhibiting macrocyclic phenylcarbamates
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
TNSN07359A1 (en) Association between ferroquine and an artemisinine derivative for treating malaria
GEP20115230B (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4
WO2007002313A3 (en) Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
ZA200709094B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
WO2008112166A3 (en) Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2006067392A3 (en) Indole derivatives for the treatment of tuberculosis
WO2007112913A3 (en) Benzimidazole derivatives
WO2007133944A3 (en) Topical administration of acyclovir
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
ZA200709096B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
DK1814848T3 (en) 2,3,4-substituted-cyclopentanones as therapeutic agents
WO2008004100A9 (en) Therapeutic compounds
WO2005070903A3 (en) Sulphonamide substituted triazines as chemokine receptor modulators
WO2007130902A3 (en) Therapeutic cyclopentane derivatives
WO2007146719A3 (en) 2-aminocarbonylphenylamino-2-phenylacetamides as factor viia inhibitors useful as anticoagulants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08726603

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008726603

Country of ref document: EP